Immunocore Holdings plc (NASDAQ:IMCR) Receives $69.18 Average Price Target from Analysts

Immunocore Holdings plc (NASDAQ:IMCR) has been given an average rating of “Moderate Buy” by the thirteen brokerages that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have issued a buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $69.18.

Several brokerages recently weighed in on IMCR. HC Wainwright reissued a “buy” rating and set a $100.00 price target on shares of Immunocore in a research report on Thursday, October 24th. Mizuho cut shares of Immunocore from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $72.00 to $38.00 in a research report on Monday, November 11th. Morgan Stanley cut their price target on Immunocore from $80.00 to $74.00 and set an “overweight” rating for the company in a report on Friday, October 11th. Oppenheimer reaffirmed an “outperform” rating and set a $89.00 price objective (up from $87.00) on shares of Immunocore in a report on Friday, August 9th. Finally, UBS Group started coverage on shares of Immunocore in a report on Thursday, October 24th. They issued a “sell” rating and a $24.00 target price for the company.

Institutional Investors Weigh In On Immunocore

Several hedge funds and other institutional investors have recently modified their holdings of IMCR. Wellington Management Group LLP grew its holdings in shares of Immunocore by 10.5% in the third quarter. Wellington Management Group LLP now owns 7,048,833 shares of the company’s stock worth $219,430,000 after purchasing an additional 668,382 shares during the last quarter. FMR LLC increased its position in shares of Immunocore by 0.5% during the third quarter. FMR LLC now owns 4,836,040 shares of the company’s stock worth $150,546,000 after acquiring an additional 23,436 shares during the period. Primecap Management Co. CA raised its stake in shares of Immunocore by 26.7% during the third quarter. Primecap Management Co. CA now owns 2,472,020 shares of the company’s stock valued at $76,954,000 after acquiring an additional 520,950 shares in the last quarter. Bellevue Group AG grew its stake in Immunocore by 4.4% in the third quarter. Bellevue Group AG now owns 1,205,464 shares of the company’s stock worth $37,526,000 after purchasing an additional 50,810 shares in the last quarter. Finally, Armistice Capital LLC grew its holdings in Immunocore by 495.1% during the 2nd quarter. Armistice Capital LLC now owns 976,000 shares of the company’s stock worth $33,077,000 after acquiring an additional 812,000 shares in the last quarter. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

Immunocore Stock Down 1.7 %

Shares of Immunocore stock opened at $31.05 on Friday. Immunocore has a 52-week low of $29.72 and a 52-week high of $76.98. The stock has a market capitalization of $1.55 billion, a price-to-earnings ratio of -32.68 and a beta of 0.72. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78. The company’s 50 day moving average price is $32.39 and its 200-day moving average price is $38.17.

Immunocore (NASDAQ:IMCR) last released its earnings results on Wednesday, November 6th. The company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.50. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The company had revenue of $80.25 million during the quarter, compared to analysts’ expectations of $78.94 million. During the same quarter last year, the business posted ($0.59) EPS. The firm’s revenue for the quarter was up 23.7% compared to the same quarter last year. Equities research analysts forecast that Immunocore will post -0.94 EPS for the current year.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.